EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting Human Telomerase in Cancer: Therapeutic Limitations and New Opportunities

Yongyi Wu, He Song

Cancer Biome and Targeted Therapy · 14.11.2026 · 279-301

DOI: 10.66505/cbtt.v1i4.66 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Biome and Targeted Therapy, online erschienen am 14.11.2026. Verfasst von Yongyi Wu und 1 weiteren Autor:innen. Die Arbeit nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universidade de Macau.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Telomerase reactivation sustains telomere maintenance in most human cancers, making the enzyme an attractive therapeutic target. However, the clinical development of telomerase inhibitors has been constrained by delayed responses, toxicity in normal proliferative tissues, and incomplete understanding of inhibitor binding to human telomerase. Structural studies of insect TERT-like proteins, ciliate and yeast holoenzymes, and human telomerase have clarified the organization of the catalytic machinery and the conformational changes required for telomeric repeat synthesis. A recent series of nine cryo-electron microscopy structures of human telomerase, with and without BIBR1532, identified an inhibitor-binding pocket between the TERT finger and palm regions. These structures revealed how BIBR1532 interferes with template-DNA duplex repositioning, providing a mechanistic explanation for its inhibition of repeat-addition processivity. Importantly, the human binding site differs substantially from the pocket previously identified in an insect TERT-like protein, illustrating the limitations of extrapolating inhibitor recognition across species. This Review integrates advances in telomerase structural biology with the therapeutic development of RNA-template antagonists, nucleotide analogs, and direct TERT inhibitors. We critically examine the translational limitations of these approaches, including the gap between biochemical inhibition and antitumor efficacy. Finally, we discuss how the newly characterized human TERT pocket could inform medicinal chemistry and computational drug design, while identifying the experimental and clinical evidence needed to establish its therapeutic potential.

Förderung

  • Universidade de Macau

Zitieren

APA

Wu, Y., & Song, H. (2026). Targeting Human Telomerase in Cancer: Therapeutic Limitations and New Opportunities. Cancer Biome and Targeted Therapy, 279-301. https://doi.org/10.66505/cbtt.v1i4.66

Vancouver

Wu Y, Song H. Targeting Human Telomerase in Cancer: Therapeutic Limitations and New Opportunities. Cancer Biome and Targeted Therapy. 2026:279-301. doi:10.66505/cbtt.v1i4.66

BibTeX
@article{Wu2026,
  author = {Wu, Yongyi and Song, He},
  title = {Targeting Human Telomerase in Cancer: Therapeutic Limitations and New Opportunities},
  journal = {Cancer Biome and Targeted Therapy},
  year = {2026},
  pages = {279--301},
  doi = {10.66505/cbtt.v1i4.66}
}
Kostenlos starten →